Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Pipeline Review, H1 2016

  • ID: 3802804
  • Drug Pipelines
  • 92 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Beta Pharma, Inc.
  • Eli Lilly and Company
  • G1 Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teijin Pharma Limited
  • MORE
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Pipeline Review, H1 2016

Summary

‘Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Pipeline Review, H1 2016’, provides in depth analysis on Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted pipeline therapeutics.

The report provides comprehensive information on the Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22)
- The report reviews Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Beta Pharma, Inc.
  • Eli Lilly and Company
  • G1 Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teijin Pharma Limited
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Overview

Therapeutics Development

Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Products under Development by Stage of Development

Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Products under Development by Therapy Area

Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Products under Development by Indication

Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Products under Development by Companies

Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Products under Development by Universities/Institutes

Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Companies Involved in Therapeutics Development

Beta Pharma, Inc.

Eli Lilly and Company

G1 Therapeutics, Inc.

Jiangsu Hengrui Medicine Co., Ltd.

Novartis AG

Onconova Therapeutics, Inc.

Pfizer Inc.

Sihuan Pharmaceutical Holdings Group Ltd.

Teijin Pharma Limited

ViroStatics srl

Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Drug Profiles

abemaciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPI-1178 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FLX-925 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-1T28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-1T38 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GZ-381 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MMD-37K - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ON-123300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palbociclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ribociclib succinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-6390 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4 and CDK6 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HSV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4, CDK6 and CDK9 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Cyclin D1, CDK6, EGFR and VEGF for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Dormant Projects

Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Discontinued Products

Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Featured News & Press Releases

Jun 03, 2016: Lilly Announces Results From MONARCH 1 Trial Of Abemaciclib Monotherapy

May 31, 2016: Lilly Announces Webcast To Discuss Abemaciclib Data

May 23, 2016: Investigational CDK4/6 inhibitor abemaciclib is active against a range of cancer types

May 18, 2016: Eli Lilly to Present final phase 2 monotherapy data on CDK 4 and 6 inhibitor abemaciclib in metastatic breast cancer at ASCO

May 18, 2016: MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer

May 10, 2016: Health Canada approves new first-line treatment for women living with metastatic breast cancer

Apr 20, 2016: Onconova Announces Novel Dual Targeting of ARK5 and CDK4/6 by Pre-clinical Compound, ON 123300, in Presentation at 2016 American Association of Cancer Research (AACR) Annual Meeting

Apr 19, 2016: Pfizer Announces Positive Top-Line Results For Phase 3 PALOMA-2 Clinical Trial Of IBRANCE (Palbociclib)

Apr 15, 2016: G1 Therapeutics to Present Preliminary clinical data on CDK4/6 Inhibitor G1T28 at the 2016 American Association for Cancer Research Annual Meeting

Apr 15, 2016: G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitor G1T38 at the 2016 American Association for Cancer Research Annual Meeting

Mar 14, 2016: New agent overcomes drug resistance in HER2-positive breast cancer preclinical study shows

Mar 07, 2016: New therapeutic target in myeloma discovered

Mar 02, 2016: Drug combination slows breast cancer spread

Feb 19, 2016: Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer

Dec 29, 2015: New breast cancer drug may be effective against other types of cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 92List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Beta Pharma, Inc., H1 2016

Pipeline by Eli Lilly and Company, H1 2016

Pipeline by G1 Therapeutics, Inc., H1 2016

Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016

Pipeline by Novartis AG, H1 2016

Pipeline by Onconova Therapeutics, Inc., H1 2016

Pipeline by Pfizer Inc., H1 2016

Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016

Pipeline by Teijin Pharma Limited, H1 2016

Pipeline by ViroStatics srl, H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 75List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Beta Pharma, Inc.
  • Eli Lilly and Company
  • G1 Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teijin Pharma Limited
  • MORE
According to the author's, recently published report 'Cyclin-Dependent Kinase 6 - Pipeline Review, H1 2016'; Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) pipeline Target constitutes close to 19 molecules. Out of which approximately 18 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the author says; Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Cell division protein kinase 6 (CDK6) is an enzyme encoded by the CDK6 gene. It is involved in initiation and maintenance of cell cycle exit during cell differentiation, prevents cell proliferation and regulates negatively cell differentiation. It is required during thymocyte development. It promotes the production of newborn neurons, probably by modulating G1 length, changes in the actin cytoskeleton including loss of stress fibers, and enhanced motility during cell differentiation. It prevents myeloid differentiation by interfering with RUNX1 and reducing its transcription transactivation activity.

The report 'Cyclin-Dependent Kinase 6 - Pipeline Review, H1 2016' outlays comprehensive information on the Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 2, 6 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 5
Beta Pharma, Inc.
Eli Lilly and Company
G1 Therapeutics, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Novartis AG
Onconova Therapeutics, Inc.
Pfizer Inc.
Sihuan Pharmaceutical Holdings Group Ltd.
Teijin Pharma Limited
ViroStatics srl
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll